This is a StreetInsider.com Premium Only Page

(PGEN) – StreetInsider.com Reports

Mar 22, 2024 02:41 AM JPMorgan Downgrades Precigen Inc. (PGEN) to Underweight

Mar 20, 2024 03:16 PM JMP Securities Reiterates Market Outperform Rating on Precigen Inc. (PGEN)

Mar 19, 2024 04:41 PM Precigen Inc. (PGEN) reports FY results

Jan 16, 2024 08:05 AM Precigen (PGEN) Granted FDA Orphan Drug Designation for PRGN-2012

Jan 8, 2024 08:37 AM Precigen (PGEN) Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024 04:40 AM Precigen Inc. (PGEN) Files $300M Mixed Shelf

Nov 9, 2023 05:00 PM Precigen Inc. (PGEN) Reports In-Line Q3 EPS

Aug 10, 2023 08:06 AM Precigen Inc. (PGEN) PT Raised to $7 at Stifel

Aug 9, 2023 08:07 AM Precigen Inc. (PGEN) Tops Q2 EPS by 2c

Aug 9, 2023 07:05 AM Precigen (PGEN) Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Jun 20, 2023 07:30 AM Precigen Inc. (PGEN) Granted FDA Breakthrough Therapy Designation for PRGN-2012

Jun 5, 2023 04:06 PM Precigen Inc. (PGEN) Reports Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells

Jun 5, 2023 05:55 AM Precigen Inc. (PGEN) Presents Positive Phase 1 Data for Off-the-Shelf PRGN-2009

May 23, 2023 02:04 AM JPMorgan Starts Precigen Inc. (PGEN) at Neutral

May 10, 2023 08:12 AM Precigen Inc. (PGEN) Misses Q1 EPS by 1c

Apr 17, 2023 09:02 AM Precigen Inc. (PGEN) Presents Preclinical Data

Apr 3, 2023 04:31 PM Precigen Inc. (PGEN) Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T

Mar 29, 2023 08:06 AM Precigen (PGEN) Reports First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007

Mar 7, 2023 07:41 AM Precigen Inc. (PGEN) PT Raised to $6.30 at Stifel

Jan 30, 2023 07:20 AM Precigen Inc. (PGEN) PT Raised to $10 at Cantor Fitzgerald

Jan 25, 2023 05:43 AM Precigen Inc. (PGEN) Prices 42.86M Share Offering at $1.75/sh

Jan 25, 2023 03:44 AM Precigen Inc. (PGEN) PT Raised to $6.10 at Stifel

Jan 24, 2023 04:05 PM Precigen Inc. (PGEN) Announces Proposed $75.0 Million Public Offering of Common Stock

Jan 24, 2023 04:02 PM Precigen Inc. (PGEN) Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for PRGN-2012

Jan 12, 2023 04:58 AM Precigen (PGEN) Provides Pipeline and Corporate Updates

Nov 18, 2022 06:03 AM Cantor Fitzgerald Starts Precigen Inc. (PGEN) at Overweight, PT $7

Nov 11, 2022 08:20 AM Precigen Inc. (PGEN) PT Lowered to $4.20 at Stifel

Nov 9, 2022 04:14 PM Precigen Inc. (PGEN) Tops Q3 EPS by 9c

Sep 21, 2022 04:31 PM Precigen (PGEN) Appoints Rutul R. Shah as COO

Sep 21, 2022 04:31 PM Precigen (PGEN) Appoints Rutul R. Shah as COO

Aug 9, 2022 06:52 AM Precigen Inc. (PGEN) PT Lowered to $6 at H.C. Wainwright

Jul 5, 2022 11:01 AM Stifel Reiterates Buy Rating, $15 Price Target on Precigen (PGEN)

Jul 5, 2022 08:05 AM Precigen Inc. (PGEN) to Divest Non-Healthcare Subsidiary Trans Ova Genetics

Apr 4, 2022 08:05 AM Precigen Inc. (PGEN) Granted Fast Track Designation for PRGN-3006 UltraCAR-T

Mar 3, 2022 06:38 AM Stifel Reiterates Buy Rating on Precigen Inc. (PGEN)

Jan 12, 2022 04:32 PM Precigen Inc. (PGEN) Announces Corporate and Pipeline Update

Dec 13, 2021 05:06 PM Precigen Inc. (PGEN) Reports Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T in Relapsed or Refractory Acute Myeloid Leukemia

Nov 4, 2021 09:15 AM Precigen Inc. (PGEN) Reports Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies

Oct 26, 2021 08:05 AM Precigen Inc. (PGEN) Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

Oct 12, 2021 08:06 AM Precigen Inc. (PGEN) Appoints Harry Thomasian Jr as CFO

Oct 1, 2021 08:09 AM Precigen (PGEN) Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Aug 9, 2021 04:43 PM Precigen Inc. (PGEN) Tops Q2 EPS by 2c

Jun 11, 2021 09:30 AM Pre-Open Stock Movers 06/11: (NOVN) (PGEN) (AMEH) Higher; (VRTX) (ELY) (SNOW) Lower (more...)

Jun 11, 2021 09:03 AM Precigen Inc. (PGEN) PT Raised to $15 at Stifel; 'Topline Data On AG019 ActoBiotics Look Encouraging'

Jun 10, 2021 06:06 PM After-Hours Stock Movers 06/10: (PGEN) (AMEH) (ARWR) Higher; (VRTX) (ELY) (SNOW) Lower (more...)

Jun 10, 2021 05:07 PM Precigen Inc. (PGEN) Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Apr 29, 2021 09:22 AM Companies with NDRs 4/29

Apr 27, 2021 07:03 AM Companies with NDRs 4/27

Apr 8, 2021 07:31 AM UPDATE: Precigen Inc. (PGEN) PT Raised to $17 at Wells Fargo After First Patient Dosing of AdenoVerse

Mar 30, 2021 04:11 PM Precigen Inc. (PGEN) Announces Departure of Chief Financial Officer